Results 141 to 150 of about 3,203 (180)
International Journal of Molecular Sciences, 2023 Effective and targeted prevention and treatment methods for acute kidney injury (AKI), a common clinical complication, still needs to be explored. Paricalcitol is a biologically active chemical that binds to vitamin D receptors in the body to exert anti ...
Xingyao Liu, Yanjun He
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2005
Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in ...
Dean M, Robinson, Lesley J, Scott
openaire +2 more sources
Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in ...
Dean M, Robinson, Lesley J, Scott
openaire +2 more sources
American Journal of Transplantation, 2013 Postkidney transplant hyperparathyroidism is a significant problem. Vitamin D receptor agonists are known to suppress parathyroid hormone (PTH) secretion.
Hatem Amer +2 more
exaly +2 more sources
Paricalcitol in the treatment of secondary hyperparathyroidism
Expert Review of Endocrinology & Metabolism, 2006Secondary hyperparathyroidism is a common complication of both chronic kidney and end-stage renal disease. Vitamin D appears to play a central role in the pathogenesis of this condition and active vitamin D replacement is usually a necessary component of its treatment.
Steven, Cheng, Daniel, Coyne
openaire +2 more sources
Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects
Biopharmaceutics & Drug Disposition, 2007AbstractParicalcitol capsules are indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease (CKD). Proton pump inhibitors are prescribed to CKD patients to treat gastroesophageal reflux. This was a single dose, crossover study evaluating the effect of omeprazole, change in gastric pH as a result thereof, on ...
Rameshraja, Palaparthy +7 more
openaire +2 more sources
International Journal of Artificial Organs, 2013 Purpose: Paricalcitol improves the inflammatory status of hemodialysis patients. PAF is a strong inflammatory mediator which is produced during hemodialysis.
Sophia N Verouti +2 more
exaly +1 more source
Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis
American Journal of Kidney Diseases, 2007Secondary hyperparathyroidism is a common complication in children receiving hemodialysis. Active vitamin D is an effective therapy, but its use is often limited by hypercalcemia and increased calcium x phosphorus (Ca x P) product. Paricalcitol, a selective vitamin D receptor activator, causes less sustained hypercalcemia and increase in Ca x P product
Larry A, Greenbaum +8 more
openaire +2 more sources
Spotlight on paricalcitol in secondary hyperparathyroidism.
Treatments in endocrinology, 2005Paricalcitol (Zemplar) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the ...
Dean M, Robinson, Lesley J, Scott
openaire +1 more source